Eisai Co., Ltd. manufactures Onivyde. [1]
What is Onivyde used for?
Onivyde is a liposomal formulation of irinotecan, a topoisomerase I inhibitor. It is indicated for the treatment of adult patients with a rare form of pancreatic cancer called pancreatic adenocarcinoma, in combination with 5-fluorouracil and leucovorin, after disease progression following gemcitabine-based chemotherapy. [2]
How does Onivyde work?
Onivyde delivers irinotecan, which works by inhibiting topoisomerase I, an enzyme essential for DNA replication and repair. By blocking this enzyme, irinotecan leads to DNA damage and cell death in cancer cells. The liposomal encapsulation of irinotecan in Onivyde helps to prolong its circulation time in the body, potentially improving its delivery to tumor sites and reducing systemic toxicity. [2]
When did Onivyde receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved Onivyde on October 24, 2015. [2]
What are the potential side effects of Onivyde?
Common side effects associated with Onivyde treatment include diarrhea, fatigue, vomiting, nausea, decreased appetite, stomatitis (mouth sores), and abdominal pain. [2] Severe side effects can include severe diarrhea, neutropenia (low white blood cell count), and hypersensitivity reactions. [2] Patients should discuss potential risks and side effects with their healthcare provider.
Are there any alternative treatments for pancreatic adenocarcinoma?
Treatment for pancreatic adenocarcinoma typically involves a combination of chemotherapy, radiation therapy, and surgery, depending on the stage of the disease. Gemcitabine-based chemotherapy is a common first-line treatment. Other chemotherapy agents and targeted therapies may be used in different clinical settings. [3]
What is the patent status of Onivyde?
Information regarding the specific patent status and expiration dates for Onivyde can be found on DrugPatentWatch.com. [4] Drug patent information is crucial for understanding when generic versions of a drug may become available.
Who are Onivyde's competitors?
While Onivyde targets a specific indication in pancreatic cancer, other drugs are used in the treatment of pancreatic adenocarcinoma, including various chemotherapy regimens and potentially other novel agents in development. The competitive landscape is dynamic and influenced by ongoing clinical trials and regulatory approvals. [3]
How is Onivyde administered?
Onivyde is administered intravenously by a healthcare professional. The dosage and frequency of administration are determined by the treating physician based on the patient's condition and response to treatment. [2]
What clinical data supports Onivyde's use?
The FDA approval of Onivyde was based on a clinical trial that demonstrated a statistically significant improvement in overall survival for patients treated with Onivyde in combination with 5-fluorouracil and leucovorin compared to those treated with 5-fluorouracil and leucovorin alone. [2]
Where can I find more information about Onivyde?
For detailed medical information about Onivyde, patients and healthcare providers can consult the official prescribing information or discuss it with a medical professional. Additional resources may be available on the manufacturer's website.
---
Sources:
[1] https://www.eisai.com/
[2] https://www.fda.gov/
[3] https://www.cancer.org/cancer/types/pancreatic-cancer/treatment.html
[4] https://drugpatentwatch.com/